Michal Dufek

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Serum inflammatory biomarkers in Parkinson's disease

Michal Dufek, Markéta Hamanová, J Lokaj et al. · Parkinsonism & Related Disorders · 2008 · 98 citations

Inflammation, Medicine, Immunology +7

Intracerebral event-related potentials to subthreshold target stimuli

Milan Brázdil, Ivan Rektor, Pavel Daniel et al. · Clinical Neurophysiology · 2001 · 92 citations

Intracerebral Event-related Potentials, Neurophysiology, Neuroanatomy +7

Interleukin-6 May Contribute to Mortality in Parkinson’s Disease Patients: A 4-Year Prospective Study

Michal Dufek, Irena Rektorová, Vojtěch Thon et al. · Parkinson s Disease · 2015 · 77 citations · Full text

Inhibition of CD40L with Frexalimab in Multiple Sclerosis

Patrick Vermersch, Cristina Granziera, Yang Mao‐Draayer et al. · New England Journal of Medicine · 2024 · 67 citations